Biogen Owes Patent Royalties For MS Drug, Genentech Says
Biogen Inc. has broken a licensing agreement with Roche Holding AG subsidiary Genentech Inc. by refusing to pay any more royalties from sales of its immunosuppressive drug Tysabri for the treatment...To view the full article, register now.
Already a subscriber? Click here to view full article